These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22558780)

  • 1. In vitro evaluation of the upper gastrointestinal passage of a novel butyrate producing isolate to counterbalance dysbiosis in inflammatory bowel disease.
    Geirnaert A; Debruyne B; Eeckhaut V; Van Immerseel F; Boon N; Van de Wiele T
    Commun Agric Appl Biol Sci; 2012; 77(1):195-9. PubMed ID: 22558780
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro evaluation of the upper gastrointestinal passage of a novel butyrate producing isolate to counterbalance dysbiosis in inflammatory bowel disease.
    Geirnaert A; Debruyne B; Eeckhaut V; Van Immerseel F; Booni N; Van de Wiele T
    Commun Agric Appl Biol Sci; 2012; 77(1):45-9. PubMed ID: 22558754
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro characterization of gastrointestinal behavior of Butyricicoccus pullicaecorum, a novel butyrate producing isolate with probiotic potential to counterbalance dysbiosis in inflammatory bowel disease.
    Geirnaert A; Steyaert A; Van den Abbeele P; Eeckhaut V; Van Immerseel F; Boon N; Van de Wiele T
    Commun Agric Appl Biol Sci; 2013; 78(1):157-63. PubMed ID: 23875313
    [No Abstract]   [Full Text] [Related]  

  • 4. Interindividual differences in response to treatment with butyrate-producing Butyricicoccus pullicaecorum 25-3T studied in an in vitro gut model.
    Geirnaert A; Wang J; Tinck M; Steyaert A; Van den Abbeele P; Eeckhaut V; Vilchez-Vargas R; Falony G; Laukens D; De Vos M; Van Immerseel F; Raes J; Boon N; Van de Wiele T
    FEMS Microbiol Ecol; 2015 Jun; 91(6):. PubMed ID: 25999470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Butyricicoccus pullicaecorum gen. nov., sp. nov., an anaerobic, butyrate-producing bacterium isolated from the caecal content of a broiler chicken.
    Eeckhaut V; Van Immerseel F; Teirlynck E; Pasmans F; Fievez V; Snauwaert C; Haesebrouck F; Ducatelle R; Louis P; Vandamme P
    Int J Syst Evol Microbiol; 2008 Dec; 58(Pt 12):2799-802. PubMed ID: 19060061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrate-producing bacteria as pharmabiotics for inflammatory bowel disease.
    Marteau P
    Gut; 2013 Dec; 62(12):1673. PubMed ID: 23461897
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing.
    Steppe M; Van Nieuwerburgh F; Vercauteren G; Boyen F; Eeckhaut V; Deforce D; Haesebrouck F; Ducatelle R; Van Immerseel F
    Food Chem Toxicol; 2014 Oct; 72():129-37. PubMed ID: 25007784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of probiotics in inflammatory bowel disease.
    Cain AM; Karpa KD
    Altern Ther Health Med; 2011; 17(1):72-9. PubMed ID: 21614946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of probiotics in inflammatory bowel diseases.
    Mach T
    J Physiol Pharmacol; 2006 Nov; 57 Suppl 9():23-33. PubMed ID: 17242485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics.
    Eeckhaut V; Ducatelle R; Sas B; Vermeire S; Van Immerseel F
    Gut; 2014 Feb; 63(2):367. PubMed ID: 23766442
    [No Abstract]   [Full Text] [Related]  

  • 11. Butyricicoccus pullicaecorum, a butyrate producer with probiotic potential, is intrinsically tolerant to stomach and small intestine conditions.
    Geirnaert A; Steyaert A; Eeckhaut V; Debruyne B; Arends JB; Van Immerseel F; Boon N; Van de Wiele T
    Anaerobe; 2014 Dec; 30():70-4. PubMed ID: 25179909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.
    Mitsuyama K; Sata M
    Expert Opin Ther Targets; 2008 Mar; 12(3):301-12. PubMed ID: 18269340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntrophomonas erecta subsp. sporosyntropha subsp. nov., a spore-forming bacterium that degrades short chain fatty acids in co-culture with methanogens.
    Wu C; Liu X; Dong X
    Syst Appl Microbiol; 2006 Sep; 29(6):457-62. PubMed ID: 16455220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of probiotics on intestinal barrier function.
    Mennigen R; Bruewer M
    Ann N Y Acad Sci; 2009 May; 1165():183-9. PubMed ID: 19538305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debugging the intestinal microbiota in IBD.
    Dessein R; Rosenstiel P; Chamaillard M
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S131-6. PubMed ID: 20117336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?
    Cary VA; Boullata J
    J Clin Nurs; 2010 Apr; 19(7-8):904-16. PubMed ID: 20492035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Probiotics in gastrointestinal pathology].
    Cijevschi C; Rezmireş A; Mihai C; Miuţescu E
    Rev Med Chir Soc Med Nat Iasi; 2002; 107(2):264-7. PubMed ID: 12638270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications of probiotics in gastrointestinal disorders in children.
    Chen CC; Walker WA
    Natl Med J India; 2011; 24(3):153-60. PubMed ID: 21786845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Probiotics for inflammatory bowel disease].
    Iizuka H; Takaishi H; Hibi T
    Nihon Rinsho; 2005 May; 63(5):776-80. PubMed ID: 15881169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding why probiotic therapies can be effective in treating IBD.
    Fedorak RN
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S111-5. PubMed ID: 18806699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.